| Trial ID: | L0274 |
| Source ID: | NCT05022693
|
| Associated Drug: |
BIO89-100
|
| Title: |
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: BIO89-100
|
| Outcome Measures: |
PK Profile of liquid formulation of BIO89-100|Evaluate the safety and tolerability of the BIO89-100 liquid formulation
|
| Sponsor/Collaborators: |
89bio, Inc.
|
| Gender: |
All
|
| Age: |
21 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
8
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
|
| Start Date: |
August 16, 2021
|
| Completion Date: |
December 21, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 2, 2022
|
| Locations: |
89bio Clinical Study Site, Chandler, Arizona, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT05022693
|
